2,6-difluoro-DL-tyrosine | 94278-64-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,6-difluoro-DL-tyrosine
• 英文别名: 2-Amino-3-(2,6-difluoro-4-hydroxyphenyl)propanoic acid
• CAS: 94278-64-5
• 化学式: C₉H₉F₂NO₃
• 分子量: 217.172
• InChiKey: GXXSRPQBOBZVBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  methyl 2,6-difluoro-4-methoxybenzoate 在 lithium aluminium tetrahydride 、 氢溴酸 、 sodium ethanolate 、 溶剂黄146 作用下， 以 乙醚 为溶剂， 反应 24.83h， 生成 2,6-difluoro-DL-tyrosine
  参考文献：
  名称：

  Synthesis of 2,6-dihalo-DL-tyrosines

  摘要：

  DOI：

  10.1021/jo00203a032

文献信息

• Diagnostic and therapeutic agents
  申请人：Taube Seija

  公开号：US20070258899A1

  公开（公告）日：2007-11-08

  Tumor targeting units are disclosed which have a peptide sequence C y —Y—G-F—X—W-G-Z-C yy (SEQ ID NO: 25), or a pharmaceutically or physiologically acceptable salt thereof. Tumor targeting agents are also disclosed having at least one targeting unit, directly or indirectly coupled to at least one effector unit. Diagnostic or pharmaceutical compositions having at least one targeting unit or at least one targeting agent, and targeting units or targeting agents for the preparation of a medicament for the treatment of cancer related diseases (including cancer), especially for the treatment of colon/colorectal cancer or its metastases are also disclosed.

  揭示了具有肽序列Cy—Y—G-F—X—W-G-Z-Cyy（序列ID编号：25）或其药学或生理上可接受的盐的肿瘤靶向单元。还披露了具有至少一个靶向单元的肿瘤靶向剂，直接或间接地偶联至至少一个效应单元。还披露了具有至少一个靶向单元或至少一个靶向剂的诊断或药物组合物，以及用于制备治疗癌症相关疾病（包括癌症）的药物的靶向单元或靶向剂，特别是用于治疗结肠/结直肠癌或其转移的靶向单元或靶向剂。
• Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
  申请人：Conde-Knape Karin

  公开号：US20070135351A1

  公开（公告）日：2007-06-14

  Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.

  本文提供了公式（I）的神经肽2受体激动剂，以及其药学上可接受的盐，衍生物和片段，其中取代基如规范中所披露的那样。这些化合物及其包含它们的制药组合物可用于治疗肥胖症和糖尿病等疾病。
• NEUROPEPTIDE-2 RECEPTOR-AGONISTS
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1962959A2

  公开（公告）日：2008-09-03
• NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2326666A1

  公开（公告）日：2011-06-01
• Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof
  申请人：Yamashita Dennis

  公开号：US20100184701A1

  公开（公告）日：2010-07-22

  This application describes a family of compounds acting as β-arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.